The 3rd International Symposium on Targeted Anticancer Therapies (TAT 2005) will be held in Amsterdam, The Netherlands, March 3-5, 2005. This conference will provide an update of recent developments concerning the new generation of rationally designed anticancer agents with well defined molecular targets in the cancer cell or the cancer cell's environment: targeted agents. The first representatives of this new generation of cancer therapies, including bevacizumab (Avastin®), cetuximab (Erbitux®) and bortezomib (Velcade®), have already been approved for the treatment of cancer patients. In addition, dozens of other targeted agents are in various stages of clinical development. It is expected that several of these agents will obtain regulatory approval in the (near) future. Thus, TAT 2005 will provide a view of the future of cancer therapy.
Among the highlights of TAT 2005 will be the Keynote Lectures on March 3. One of these keynotes, the 2005 NDDO Honorary Lecture (Thursday, March 3, 2005; 13:15-13:55 hours), will be presented by Professor Daniel D. Von Hoff of the University of Arizona. He will address the question why certain cancer patients respond well to targeted agents, whereas others do not. Professor Von Hoff is one of the leading pioneers in the development of this new generation of anticancer agents.
Another highlight of the TAT 2005 program will be a Plenary Session on Friday, March 4 (8:30-10:30 hours) on emerging treatment options for renal cell cancer. Remarkably, several new targeted agents show good results in clinical studies in patients with metastasized renal cell cancer, a disease with very few effective treatment options today. The Plenary Session on March 4 will feature six promising new agents, which will be reviewed and discussed by internationally renowned clinical experts who have hands-on experience with these agents in clinical trials.
The meeting program will also cover updates on the continued clinical development of various recently approved targeted agents, including the EGFR inhibitors gefitinib (Iressa®) and erlotinib (Tarceva®) (Professor Giuseppe Giaccone, Amsterdam; Thursday, March 3, 15:50-16:20 hours) and cetuximab (Erbitux®) (Professor José Baselga, Barcelona; Thursday, March 3, 16:20-16:45 hours) and the anti-angiogenic agent, bevacizumab (Avastin®) (Professor Joan Schiller, Madison, Wisconsin; Saturday, March 5, 13:30-13:55 hours).
About 400 delegates, mainly scientists and clinicians from Europe and North America, are expected to attend the conference. The program will last 3 days and will encompass approximately 40 plenary lectures. TAT 2005 is organized by the Amsterdam-based NDDO Research Foundation and the European Society for Medical Oncology (ESMO) in collaboration with Professor Giuseppe Giaccone, Head, Department of Medical Oncology, VU University medical center, Amsterdam, who will serve as Symposium President.
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
The life which is unexamined is not worth living.